ARRAY BIOPHARMA INC

ARRAY BIOPHARMA INC specializes in the manufacturing of pharmaceutical preparations, focusing on the development and production of active pharmaceutical ingredients and finished dosage forms in compliance with current Good Manufacturing Practices (cGMP). Their technical expertise lies in scale-up processes, formulation development, and quality control systems tailored for regulated therapeutic products. The company’s capabilities center on end-to-end pharmaceutical manufacturing workflows, including analytical method validation, batch documentation, and supply chain integrity for federally procured medications. Their specialization in precision manufacturing ensures consistency and compliance in drug products intended for clinical and veteran care applications. The contractor has demonstrated direct engagement with the Department of Veterans Affairs, delivering pharmaceutical manufacturing services under extended contractual arrangements. This relationship suggests a sustained role in supporting VA’s medicinal supply chain, likely providing specialty or chronic disease therapeutics critical to veteran health outcomes. The nature of the contract extension implies reliability, regulatory adherence, and consistent performance in meeting agency-specific pharmaceutical requirements. ARRAY BIOPHARMA INC operates exclusively within the pharmaceutical preparation manufacturing sector (NAICS 325412), positioning itself as a niche producer of FDA-regulated drug products. The company’s market focus is narrow but deeply aligned with government healthcare needs, particularly in the delivery of stable, high-quality pharmaceuticals for institutional use. This vertical specialization distinguishes them from broad-spectrum drug manufacturers by emphasizing precision, regulatory compliance, and mission-critical supply continuity. As a small business structured as a 2L entity based in Boulder, Colorado, ARRAY BIOPHARMA INC maintains a focused operational footprint with no federal certifications on record. Their geographic presence supports regional biopharma ecosystems while serving federal procurement channels through direct manufacturing capabilities. The company’s government market positioning is defined by its ability to deliver compliant, scalable pharmaceutical outputs to specialized public health agencies.